What new immunotherapy strategies is Feng developing for liver cancer?

Question

Accepted Answer

Feng is developing novel immunotherapy strategies for liver cancer that are independent of immune checkpoint inhibitors.

Feng Gensheng, a notable liver cancer researcher, has joined the Shenzhen Bay Laboratory (SZBL) in China, bringing his expertise in liver cancer recurrence mechanisms and immunotherapy. His recent research efforts are directed towards creating new therapeutic approaches for liver cancer that do not depend on immune checkpoint inhibitors. This work builds upon his established career, which includes the discovery of the enzyme SHP2 and a strong interest in tumour immunology cultivated during his studies.
Focus on Non-Immune Checkpoint Inhibitor Strategies

Feng's current research agenda specifically targets the development of new immunotherapy strategies for liver cancer. These strategies are designed to function independently of immune checkpoint inhibitors, a common class of drugs used in cancer treatment. The goal is to explore alternative pathways for stimulating the immune system to fight liver cancer.
Background in Liver Cancer Research

Feng's scientific contributions are primarily in the field of liver cancer. His research has focused on understanding the underlying mechanisms that lead to the recurrence of liver cancer after initial treatment. This foundational knowledge is crucial for developing more effective therapies.
Discovery of SHP2 Enzyme

A significant contribution by Feng to the scientific community was the discovery of SHP2, a new enzyme. This discovery, published in the journal Science, has implications for understanding cellular signalling pathways relevant to cancer development and progression.
Career Transition to Shenzhen Bay Laboratory

Feng has transitioned his career from the University of California, San Diego (UCSD) to the Shenzhen Bay Laboratory (SZBL), a research platform established by Guangdong province and the city of Shenzhen. This move occurred as US universities faced potential funding cuts during the Trump administration, with UCSD anticipating significant annual losses. Feng's appointment at SZBL is as the director of its Cancer Research Institute.

Reading history

Hide →

This history is cleared when the page is closed.

What new immunotherapy strategies is Feng developing for liver cancer?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends